ArticleAntimicrobial agents and chemotherapy2015
Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 57 citations in OpenAlex.
- CSA-13 treatment in a murine model of Pseudomonas pneumonia-induced sepsis and its effects on renal injury, inflammation, and glycocalyx derangement.The Journal of antibiotics · 2026Article
- Biological properties of ceragenin-coated metal nanoparticles - future challenges and perspectives in clinical practice.Nanomedicine (London, England) · 2025Review
- Structure, Function, and Regulation of LytA: TheMicroorganisms · 2025Review
- Bactericidal activity of ceragenin CSA-13, CSA-44 and CSA-131 against bacteria causing bloodstream infections.Frontiers in microbiology · 2025Article
- Natural Antimicrobial Peptides and Their Synthetic Analogues for Effective Oral Microflora Control and Oral Infection Treatment-The Role of Ceragenins in the Development of New Therapeutic Methods.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Efficacy of Ceragenins in Controlling the Growth of Oral Microorganisms: Implications for Oral Hygiene Management.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Ceragenins and Ceragenin-Based Core-Shell Nanosystems as New Antibacterial Agents against Gram-Negative Rods Causing Nosocomial Infections.Pathogens (Basel, Switzerland) · 2023Review
- Lipophosphonoxins-A Novel Group of Broad Spectrum Antibacterial Compounds.Pharmaceutics · 2023Review
- Local Antibiotic Delivery Options in Prosthetic Joint Infection.Antibiotics (Basel, Switzerland) · 2023Review
- Ceragenins exhibit bactericidal properties that are independent of the ionic strength in the environment mimicking cystic fibrosis sputum.Frontiers in microbiology · 2023Article
- Ceragenin CSA-13 displays high antibacterial efficiency in a mouse model of urinary tract infection.Scientific reports · 2022Article
- Effects of Ceragenins and Antimicrobial Peptides on the A549 Cell Line and an In Vitro Co-Culture Model of A549 Cells andPathogens (Basel, Switzerland) · 2022Article
- LEGO-Lipophosphonoxins: A Novel Approach in Designing Membrane Targeting Antimicrobials.Journal of medicinal chemistry · 2022Article
- Bactericidal Activity of Ceragenin in Combination with Ceftazidime, Levofloxacin, Co-Trimoxazole, and Colistin against the Opportunistic PathogenPathogens (Basel, Switzerland) · 2022Article
- Ceragenin CSA-44 as a Means to Control the Formation of the Biofilm on the Surface of Tooth and Composite Fillings.Pathogens (Basel, Switzerland) · 2022Article
- Emerging and future strategies in the management of recalcitrant Candida auris.Medical mycology · 2022Review
- Ceragenin-Coated Non-Spherical Gold Nanoparticles as Novel Candidacidal Agents.Pharmaceutics · 2021Article
- Article
- Synergistic Activity of Ceragenins Against Carbapenem-Resistant Acinetobacter baumannii Strains in Both Checkerboard and Dynamic Time-Kill Assays.Current microbiology · 2020Article
- Recombinant Human Plasma Gelsolin Stimulates Phagocytosis while Diminishing Excessive Inflammatory Responses in Mice withInternational journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceragenins constitute a novel family of cationic antibiotics characterized by a broad spectrum of antimicrobial activities, which have mostly been assessed in vitro. Using a polarized human lung epithelial cell culture system, we evaluated the antibacterial activities of the ceragenin CSA-13 against two strains of Pseudomonas aeruginosa (PAO1 and Xen5). Additionally, the biodistribution and bactericidal activity of a CSA-13-IRDye 800CW derivate were assessed using an animal model of peritoneal infection after PAO1 challenge. In cell culture, CSA-13 bactericidal activities against PAO1 and Xen5 were higher than the activities of the human cathelicidin peptide LL-37. Increased CSA-13 activity was observed in polarized human lung epithelial cell cultures subjected to butyric acid treatment, which is known to increase endogenous LL-37 production. Eight hours after intravenous or intraperitoneal injection, the greatest CSA-13-IRDye 800CW accumulation was observed in mouse liver and kidneys. CSA-13-IRDye 800CW administration resulted in decreased bacterial outgrowth from abdominal fluid collected from animals subjected to intraperitoneal PAO1 infection. These observations indicate that CSA-13 may synergistically interact with antibacterial factors that are naturally present at mucosal surfaces and it maintains its antibacterial activity in the infected abdominal cavity. Cationic lipids such as CSA-13 represent excellent candidates for the development of new antibacterial compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.